Table 1 Multiple functions exerted by m6A RNA methylation in various diseases
Disease | Related targets | M6A component | Function | Role in diseases | Source of experimental evidence | Regulation | Year | Refs |
|---|---|---|---|---|---|---|---|---|
AML | c-MYC, BCL2, PTEN | METTL3 | Writers | oncogene | HSPCs, AML MOLM-13 cells | Up-regulation | 2017 | [70] |
AML | CEBPZ | METTL3 | Writers | oncogene | AML cells, immunodeficient mice | Up-regulation | 2017 | [23] |
AML | MYB, MYC | METTL14 | Writers | oncogene | AML cell lines | Up-regulation | 2017 | [68] |
AML | mTOR | WTAP | Writers | oncogene | 511 newly diagnosed AML patient samples, Ba/F3 cell line, AML cell lines | Down-regulation | 2014 | [69] |
AML | ASB2, RARA | FTO | Erasers | oncogene | MONOMAC-6 and NB4 cells | Down-regulation | 2017 | [67] |
AML | MYC, CEBPA | FTO | Erasers | oncogene | 27 human leukemia cell lines | Up-regulation | 2018 | [24] |
AML | Tal1… | YTHDF2 | Readers | anti- oncogene | HSPCs, mouse… | Down-regulation | 2018 | [72] |
Bladder cancer | AFF4, MYC | METTL3 | Writers | oncogene | Bladder cancer cell lines, mouse bladder cancer samples | Up-regulation | 2019 | [44] |
Breast cancer | HBXIP | METTL3 | Writers | oncogene | 24 clinical tumor samples, MCF-7, MDA-MB-468 cells | Up-regulation | 2018 | [78] |
Breast cancer | NANOG | ALKBH5 | Erasers | oncogene | BCSCs | Up-regulation | 2016 | [79] |
CRC | WT1, TBL1 | WTAP | Writers | oncogene | 115 patient samples with CRC, colon cancer cell lines | Down-regulation | 2016 | [81] |
Endometrial cancer | AKT… | METTL3/14 | Writers | anti- oncogene | Cancer samples, endometrial cancer cell lines, mice | Down-regulation | 2018 | [66] |
GBM | ADAM19 | METTL3/14 | Writers | anti- oncogene | GSC, GSC-grafted mice | Down-regulation | 2017 | [74] |
GBM | FOXM1 | ALKBH5 | Erasers | oncogene | GSCs | Up-regulation | 2017 | [73] |
HCC | SOCS2 | METTL3 | Writers | oncogene | MHCC97L, Huh-7 and HepG2 cell lines, BABL/cAnN-nude mice | Down-regulation | 2017 | [37] |
HCC | miR-126 | METTL14 | Writers | anti-oncogene | HepG2 cell | Up-regulation | 2017 | [26] |
HCC | miR-145 | YTHDF2 | Readers | oncogene | clinical tissue, HepG2 cell line | miR-145 suppresses YTHDF2 | 2017 | [77] |
HCC, AML… | SRF… | IGF2BP1 | Readers | oncogene | HepG2, K562, hESCs cell lines… | Up-regulation | 2019 | [16] |
impaired fertility | Uhrf1… | ALKBH5 | Erasers | spermatogenesis | HeLa cells, mouse testicular cells | Up-regulation | 2013 | [14] |
Lung cancer | EGFR, TAZ | METTL3 | Writers | oncogene | Human lung cancer cell lines, HeLa, HEK293T cells | Up-regulation | 2016 | [46] |
NPC | ZNF750, FGF14 | METTL3 | Writers | oncogene | NPC biopsy samples and cell lines | Down-regulation | 2018 | [45] |
Obesity | SRSF2 | FTO | Erasers | adipogenesis | 3 T3-L1 cell | Decreased RNA binding ability | 2014 | [28] |
Pancreatic cancer | RBM17… | METTL3 | Writers | oncogene | Pancreatic cancer cell lines | Up-regulation | 2018 | [31] |